Patient advocacy helps patients weigh up gene therapy trial risk/benefits

Open access


The investigators behind the first gene therapy trial with adenoassociated virus 8 (AAV8) Factor IX appointed a patient ombudsperson to help ensure participants were able to give truly informed consent. The experiences and challenges of the ombudsperson, who met with the first six UK-based patients, are described. It was stressed to potential participants that altruism, rather than any expectation of clinical benefit, should be the primary motivation to taking part. At the same time a sober assessment of the potential risks to their safety needed to be made.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Nathwani AC Tuddenham EG Rangarajan S et al. AdenovirusPassociated virus vectorPmediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357P65. doi:

    • Crossref
    • Export Citation
  • 2. Nathwani AC Reiss UM Tuddenham EG et al. LongPterm safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371: 1994P2004. doi:

    • Crossref
    • Export Citation
Journal information
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 125 70 2
PDF Downloads 69 33 0